Printer Friendly
The Free Library
19,595,263 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Change in Director of Research at MPI Research.


MATTAWAN, Mich. -- Jim Laveglia, PhD, has passed the baton of Director of Research at MPI Research to Tina Rogers, PhD, MBA, DABT, formerly the company's Discovery Center Director. In his new role as Executive Vice President, Dr. Laveglia will focus on business development and will continue to serve on the company's Corporate Management Team and Board of Directors.

Dr. Laveglia, who joined MPI Research soon after its inception in the mid-1990's, became Director of Research in February 1997. He earned his PhD from Iowa State University and has more than 33 years of experience as a toxicologist. Prior to MPI Research, he served as Director of Toxicology and Animal Metabolism at Ricerca, Inc. In his numerous leadership positions in the chemical industry and with contract toxicology laboratories, he has directed the activities of toxicologists, pathologists, technical staff, report-preparation staff, and overall corporate operations.

Tina Rogers, PhD, MBA, DABT joined MPI Research in 2007 as Director of the Discovery Center and Associate Director of Research. In her new role as Director of Research and member of the Corporate Management Team, Dr. Rogers will continue to lead major growth initiatives for the company. With over 20 years of experience in the CRO industry, she has held key leadership positions, most recently as Vice President of Drug Development at Southern Research Institute. Dr. Rogers received her PhD from the Medical University of South Carolina in molecular and cellular biology and pathobiology, and completed postdoctoral fellowships at Harvard Medical School and Tufts University School of Medicine. She currently serves on the MBA Advisory Board at the Auburn University School of Business and is a member of the Gerson Lehman Group Healthcare Council.

Company Chairman and CEO Bill Parfet, MBA states, "These are exciting but challenging economic times for the pharmaceutical and biotech customers that we serve. The contract research organizations that partner with them in moving their drug and device candidates forward need to demonstrate sharper business acumen and greater scientific expertise than ever before and Drs. Laveglia and Rogers bring those attributes to the table. With them as essential members of our leadership team, I am confident that MPI Research can meet market needs better than any other CRO."

MPI Research, with global headquarters in Mattawan, Michigan, is one of the world's leading providers of comprehensive preclinical and early clinical research and development services. Learn more about the company's commitment to be the best at www.mpiresearch.com.

COPYRIGHT 2009 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Aug 13, 2009
Words:405
Previous Article:Gold Reserve Announces Conference Call to Discuss 2009 Second Quarter Results.
Next Article:Micromem Technologies Executes Manufacturing Supply Agreement with Life Medical Technologies.
Topics:



Related Articles
NEC DELIVERS SUPERCOMPUTER TO EARTH SIMULATOR CENTER.
Maitake Products, Inc. (MPI): mastering medicinal mushrooms.
MPI Research Selects ISIToolBox to Prepare Sponsor Companies for Electronic Submissions.
Medicilon/MPI Preclinical Research-Shanghai Receives AAALAC Certification.
Medicilon/MPI Preclinical Research-Shanghai Receives AAALAC Certification.
Extract of new mushroom targets support of breast health.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles